Transmitted drug resistance in the CFAR network of integrated clinical systems Cohort: Prevalence and effects on pre-therapy CD4 and viral load

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Poon, Art F Y ^a   Aldous, Jeannette L ^b   Mathews, W Christopher ^b   Kitahata, Mari ^c   Kahn, James S ^d   Saag, Michael S ^e   Rodríguez, Benigno ^f   Boswell, Stephen L ^g   Frost, Simon D W ^h   Haubrich, Richard H ^b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; BAYES THEOREM; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; NORTH AMERICA; PREVALENCE; PROBABILITY; RISK FACTOR; SEQUENCE ANALYSIS; VIRUS LOAD; DRUG EFFECT; FEMALE; GENETICS; MALE; MUTATION; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV-1; HUMANS; MALE; MUTATION; NORTH AMERICA; VIRAL LOAD;

EID: 79959297243     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021189     Document Type: Article

References (45)

1. Booth CL, Geretti AM, (2007) Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-56.
2. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, et al. (2010) Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 24: 1203-12.
3. Pao D, Andrady U, Clarke J, Dean G, Drake S, et al. (2004) Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 37: 1570-3.
4. Little SJ, Frost SDW, Wong JK, Smith DM, Kosakovsky Pond SL, et al. (2008) Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 82: 5510-5518.
5. Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, et al. (2010) Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis 201: 672-80.
6. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
7. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 199: 693-701.
8. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, et al. (2005) Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 38: 37-42.
9. Mammano F, Trouplin V, Zennou V, Clavel F, (2000) Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 74: 8524-31.
10. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, et al. (2004) Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 78: 603-11.
11. Cong M, Heneine W, García-Lerma JG, (2007) The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 81.
12. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, et al. (2009) In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 83: 2038-43.
13. Balotta C, Berlusconi A, Pan A, Violin M, Riva C, et al. (2000) Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently-infected individuals. Antivir Ther 5: 7-14.
14. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, et al. (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288: 181-8.
15. Shet A, Leslie B, Hiroshi M, Mehandru S, Chung C, et al. (2006) Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. JAIDS 41: 439-446.
16. Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, et al. (2006) Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther 11: 173-8.
17. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, et al. (2006) The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 20: 21-8.
18. Kitahata MM, Rodriguez B, Haubrich R, Boswell S, Mathews WC, et al. (2008) Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol 37: 948-55.
19. Robins JM, Hernán MA, Brumback B, (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-60.
20. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, et al. (2006) Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 3: e356.
21. Taylor JM, Wang Y, Ahdieh L, Chmiel JS, Detels R, et al. (2000) Causal pathways for CCR5 genotype and HIV progression. J Acquir Immune Defic Syndr 23: 160-71.
22. Gotoh O, (1982) An improved algorithm for matching biological sequences. J Mol Biol 162: 705-708.
23. Kosakovsky Pond SL, Frost SDW, Muse SV, (2005) HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676-679.
24. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
25. Liu TF, Shafer RW, (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-18.
26. Venables WN, Ripley BD, (2002) Modern Applied Statistics with S. Springer.
27. Burnham KP, Anderson DR, (2004) Multimodel inference: understanding AIC and BIC in model selection. Sociol Method Res 33: 261-304.
28. Lumley T, (2004) Analysis of Complex Survey Samples. Journal of Statistical Software 9: 1-19.
29. Poon AFY, Kosakovsky Pond SL, Richman DD, Frost SDW, (2007) Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J Virol 81: 13598-607.
30. Pearl J, (1988) Probabilistic reasoning in intelligent systems: Networks of plausible inference San Mateo, Calif. Morgan Kaufmann Publishers.
31. Wensing AMJ, van de Vijver DA, Angarano G, Asjö B, Balotta C, et al. (2005) Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192: 958-66.
32. Yerly S, von Wyl V, Ledergerber B, Böni J, Schüpbach J, et al. (2007) Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21: 2223-9.
33. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-33.
34. Wilkin TJ, Gulick RM, (2008) When to start antiretroviral therapy? Clin Infect Dis 47: 1580-6.
35. Hernán MA, Brumback B, Robins JM, (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: 561-70.
36. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, et al. (1996) Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271: 1282-5.
37. Götte M, Arion D, Parniak MA, Wainberg MA, (2000) The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 74: 3579-85.
38. Devereux HL, Emery VC, Johnson MA, Loveday C, (2001) Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 65: 218-24.
39. von Wyl V, Ehteshami M, Symons J, Bürgisser P, Nijhuis M, et al. (2010) Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J Infect Dis 201: 1054-62.
40. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, et al. (2006) Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 20: 795-803.
41. Harrison L, Castro H, Cane P, Pillay D, Booth C, et al. (2010) The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 24: 1917-22.
42. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ, (2000) Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 74: 6262-8.
43. Wei X, Liang C, Götte M, Wainberg MA, (2003) Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 311: 202-12.
44. Huang H, Chopra R, Verdine GL, Harrison SC, (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282: 1669-75.
45. García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W, (2004) Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol 78: 7545-52.